FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis | Eli Lilly and Company - Investors | Eli Lilly and Company
investor.lilly.comSubmitted by lillycom9342 in business
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.